NASDAQ:AVEO - AVEO Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.16 0.00 (0.00 %)
(As of 05/21/2018 04:00 PM ET)
Previous Close$2.16
Today's Range$2.13 - $2.22
52-Week Range$0.63 - $4.24
Volume1.02 million shs
Average Volume1.72 million shs
Market Capitalization$256.75 million
P/E Ratio-13.50
Dividend YieldN/A
Beta1.41

About AVEO Pharmaceuticals (NASDAQ:AVEO)

AVEO Pharmaceuticals logoAVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase 3 TIVO-3 trial of tivozanib for the treatment of advanced RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor, for the treatment of advanced RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody, in Phase I and Phase II clinical trials in squamous cell carcinoma of the head and neck, metastatic pancreatic ductal cancer, and acute myeloid leukemia; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company's preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. It has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.

Receive AVEO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVEO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:AVEO
CUSIP05358810
Phone617-588-1960

Debt

Debt-to-Equity Ratio-0.36
Current Ratio1.34
Quick Ratio1.34

Price-To-Earnings

Trailing P/E Ratio-13.50
Forward P/E Ratio-8.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$7.58 million
Price / Sales33.87
Cash FlowN/A
Price / CashN/A
Book Value($0.34) per share
Price / Book-6.35

Profitability

EPS (Most Recent Fiscal Year)($0.16)
Net Income$-65,020,000.00
Net Margins-1,073.16%
Return on EquityN/A
Return on Assets-39.88%

Miscellaneous

Employees19
Outstanding Shares118,870,000

AVEO Pharmaceuticals (NASDAQ:AVEO) Frequently Asked Questions

What is AVEO Pharmaceuticals' stock symbol?

AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."

How were AVEO Pharmaceuticals' earnings last quarter?

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced its quarterly earnings data on Tuesday, May, 8th. The biopharmaceutical company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.00. The biopharmaceutical company had revenue of $1.03 million for the quarter, compared to analyst estimates of $0.98 million. View AVEO Pharmaceuticals' Earnings History.

What price target have analysts set for AVEO?

4 Wall Street analysts have issued 1 year price objectives for AVEO Pharmaceuticals' stock. Their forecasts range from $3.00 to $5.00. On average, they expect AVEO Pharmaceuticals' stock price to reach $4.1667 in the next year. View Analyst Ratings for AVEO Pharmaceuticals.

Are investors shorting AVEO Pharmaceuticals?

AVEO Pharmaceuticals saw a increase in short interest in April. As of April 30th, there was short interest totalling 9,843,720 shares, an increase of 17.0% from the April 13th total of 8,416,656 shares. Based on an average trading volume of 1,255,958 shares, the short-interest ratio is currently 7.8 days. Approximately 10.3% of the shares of the company are sold short.

Who are some of AVEO Pharmaceuticals' key competitors?

Who are AVEO Pharmaceuticals' key executives?

AVEO Pharmaceuticals' management team includes the folowing people:
  • Mr. Michael P. Bailey, CEO, Pres & Director (Age 53)
  • Dr. Michael N. Needle M.D., Chief Medical Officer (Age 58)
  • Mr. Matthew D. Dallas, Chief Financial Officer (Age 43)
  • Dr. Emile Farhan Ph.D., VP of Technical Operations
  • Ms. Karuna Rubin J.D., VP of Legal Affairs and Corp. Sec.

Has AVEO Pharmaceuticals been receiving favorable news coverage?

Media stories about AVEO stock have been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. AVEO Pharmaceuticals earned a media sentiment score of 0.01 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 44.49 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are AVEO Pharmaceuticals' major shareholders?

AVEO Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include venBio Select Advisor LLC (2.72%), Point72 Asset Management L.P. (0.79%), Tibra Equities Europe Ltd (0.22%), X Square Capital LLC (0.19%), Spark Investment Management LLC (0.14%) and Element Capital Management LLC (0.11%). Company insiders that own AVEO Pharmaceuticals stock include Equity Opportunities Iv Growth, Peter J Barris and Ravi Viswanathan. View Institutional Ownership Trends for AVEO Pharmaceuticals.

Which major investors are selling AVEO Pharmaceuticals stock?

AVEO stock was sold by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, JPMorgan Chase & Co. and Spark Investment Management LLC. View Insider Buying and Selling for AVEO Pharmaceuticals.

Which major investors are buying AVEO Pharmaceuticals stock?

AVEO stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Tibra Equities Europe Ltd, Element Capital Management LLC, Birchview Capital LP, Verition Fund Management LLC and X Square Capital LLC. Company insiders that have bought AVEO Pharmaceuticals stock in the last two years include Equity Opportunities Iv Growth, Peter J Barris and Ravi Viswanathan. View Insider Buying and Selling for AVEO Pharmaceuticals.

How do I buy shares of AVEO Pharmaceuticals?

Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AVEO Pharmaceuticals' stock price today?

One share of AVEO stock can currently be purchased for approximately $2.16.

How big of a company is AVEO Pharmaceuticals?

AVEO Pharmaceuticals has a market capitalization of $256.75 million and generates $7.58 million in revenue each year. The biopharmaceutical company earns $-65,020,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. AVEO Pharmaceuticals employs 19 workers across the globe.

How can I contact AVEO Pharmaceuticals?

AVEO Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-588-1960 or via email at [email protected]


MarketBeat Community Rating for AVEO Pharmaceuticals (AVEO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  234 (Vote Outperform)
Underperform Votes:  228 (Vote Underperform)
Total Votes:  462
MarketBeat's community ratings are surveys of what our community members think about AVEO Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVEO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AVEO Pharmaceuticals (NASDAQ:AVEO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for AVEO Pharmaceuticals in the last 12 months. Their average twelve-month price target is $4.1667, suggesting that the stock has a possible upside of 92.90%. The high price target for AVEO is $5.00 and the low price target for AVEO is $3.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.1667$4.1667$4.1667$4.1667
Price Target Upside: 92.90% upside34.41% upside34.41% upside37.97% upside

AVEO Pharmaceuticals (NASDAQ:AVEO) Consensus Price Target History

Price Target History for AVEO Pharmaceuticals (NASDAQ:AVEO)

AVEO Pharmaceuticals (NASDAQ:AVEO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/16/2018B. RileyReiterated RatingBuy$5.00HighView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuyN/AView Rating Details
8/28/2017Piper Jaffray CompaniesBoost Price TargetOverweight$3.80 ➝ $4.50HighView Rating Details
7/13/2017FBR & CoReiterated RatingOutperform$3.00HighView Rating Details
(Data available from 5/21/2016 forward)

Earnings

AVEO Pharmaceuticals (NASDAQ:AVEO) Earnings History and Estimates Chart

Earnings by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)

AVEO Pharmaceuticals (NASDAQ:AVEO) Earnings Estimates

2018 EPS Consensus Estimate: ($0.25)
2019 EPS Consensus Estimate: ($0.31)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.08)($0.06)($0.07)
Q2 20182($0.06)($0.06)($0.06)
Q3 20182($0.06)($0.06)($0.06)
Q4 20182($0.06)($0.05)($0.06)
Q1 20191($0.04)($0.04)($0.04)
Q2 20191($0.04)($0.04)($0.04)
Q3 20192($0.27)($0.04)($0.16)
Q4 20192($0.10)($0.04)($0.07)

AVEO Pharmaceuticals (NASDAQ AVEO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q1 2018($0.07)($0.0750)$0.98 million$1.03 millionViewN/AView Earnings Details
3/13/2018Q4 2017($0.02)($0.08)$1.00 million$0.08 millionViewN/AView Earnings Details
11/7/2017Q3 2017($0.05)($0.02)$6.50 million$4.61 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.10)($0.08)$4.00 million$0.35 millionViewN/AView Earnings Details
5/4/2017Q1 2017($0.12)($0.1160)$2.53 millionViewN/AView Earnings Details
3/22/2017Q4 2016($0.09)($0.11)$0.13 millionViewN/AView Earnings Details
11/4/2016Q3 2016($0.1150)($0.07)$0.99 millionViewN/AView Earnings Details
8/4/2016Q2 2016($0.14)($0.13)$0.19 millionViewN/AView Earnings Details
5/10/2016Q1($0.12)($0.13)$1.00 million$1.20 millionViewN/AView Earnings Details
3/15/2016Q415($0.04)($0.11)$3.60 millionViewN/AView Earnings Details
11/9/2015Q315($0.09)$0.14$15.16 millionViewN/AView Earnings Details
8/10/2015Q2($0.16)($0.10)$0.13 millionViewListenView Earnings Details
5/7/2015Q115($0.27)($0.21)$0.13 millionViewN/AView Earnings Details
3/6/2015Q314($0.28)($0.27)$0.12 millionViewListenView Earnings Details
11/5/2014Q3 2014($0.27)($0.28)$0.33 million$0.87 millionViewN/AView Earnings Details
8/11/2014Q214($0.38)($0.35)$0.35 million$1.85 millionViewN/AView Earnings Details
5/7/2014Q1 2014($0.33)($0.12)$0.38 million$15.29 millionViewN/AView Earnings Details
3/13/2014Q413($0.33)($0.32)$0.14 million$0.3230 millionViewListenView Earnings Details
11/4/2013Q313($0.47)($0.47)$0.23 million$0.32 millionViewN/AView Earnings Details
8/1/2013Q213($0.56)($0.62)$4.30 million$0.32 millionViewN/AView Earnings Details
4/29/2013Q1 2013($0.72)($0.69)$2.52 million$0.3230 millionViewListenView Earnings Details
2/13/2013Q4 2012($0.77)($0.49)$14.49 million$15.53 millionViewN/AView Earnings Details
10/30/2012Q312($0.87)($0.69)$6.57 million$1.02 millionViewN/AView Earnings Details
8/2/2012($0.82)($0.68)ViewN/AView Earnings Details
5/3/2012($0.78)($0.77)ViewN/AView Earnings Details
2/14/2012($0.64)($0.58)ViewN/AView Earnings Details
11/2/2011($0.46)($0.55)ViewN/AView Earnings Details
7/28/2011($0.80)($0.16)ViewN/AView Earnings Details
4/28/2011Q1 2011($0.57)$2.28ViewN/AView Earnings Details
2/16/2011Q4 2010($0.64)($0.30)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.62)($0.60)ViewN/AView Earnings Details
7/29/2010Q2 2010($0.35)($0.50)ViewN/AView Earnings Details
4/29/2010Q1 2010($0.81)($2.27)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

AVEO Pharmaceuticals (NASDAQ:AVEO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

AVEO Pharmaceuticals (NASDAQ AVEO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.40%
Institutional Ownership Percentage: 50.23%
Insider Trading History for AVEO Pharmaceuticals (NASDAQ:AVEO)
Institutional Ownership by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)

AVEO Pharmaceuticals (NASDAQ AVEO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/21/2018Equity Opportunities Iv GrowthMajor ShareholderBuy236,479$2.13$503,700.27View SEC Filing  
5/17/2018Ravi ViswanathanMajor ShareholderBuy184,179$2.13$392,301.27View SEC Filing  
5/8/2018Ravi ViswanathanMajor ShareholderBuy70,873$2.13$150,959.49View SEC Filing  
4/10/2018Peter J BarrisMajor ShareholderBuy920,976$2.30$2,118,244.80View SEC Filing  
4/6/2018Ravi ViswanathanMajor ShareholderBuy685,676$2.24$1,535,914.24View SEC Filing  
3/28/2017Equity Opportunities Iv GrowthMajor ShareholderBuy6,000,000$0.50$3,000,000.00View SEC Filing  
1/16/2015Matthew D DallasVPSell3,075$0.82$2,521.50View SEC Filing  
1/7/2015Michael P BaileyCEOSell4,484$0.80$3,587.20View SEC Filing  
1/30/2014Joseph VittiglioSVPSell5,430$1.64$8,905.2034,121View SEC Filing  
3/14/2013David Brannon JohnstonCFOSell1,061$7.34$7,787.74View SEC Filing  
3/7/2013Henri A TermeerDirectorBuy55,499$6.73$373,508.27View SEC Filing  
12/13/2012Ngoc Tuan HaCEOBuy75,000$6.65$498,750.00View SEC Filing  
12/13/2012Robert C YoungDirectorBuy2,371$6.78$16,075.38View SEC Filing  
12/3/2012Robert C YoungDirectorBuy1,250$6.41$8,012.50View SEC Filing  
9/13/2012David Brannon JohnstonCFOSell1,386$10.60$14,691.60View SEC Filing  
8/8/2012Robert C YoungDirectorBuy1,000$8.63$8,630.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

AVEO Pharmaceuticals (NASDAQ AVEO) News Headlines

Source:
DateHeadline
Equity Opportunities Iv Growth Purchases 236,479 Shares of AVEO Pharmaceuticals, Inc. (AVEO) StockEquity Opportunities Iv Growth Purchases 236,479 Shares of AVEO Pharmaceuticals, Inc. (AVEO) Stock
www.americanbankingnews.com - May 21 at 7:34 PM
AVEO Pharmaceuticals, Inc. (AVEO) Major Shareholder Buys $392,301.27 in StockAVEO Pharmaceuticals, Inc. (AVEO) Major Shareholder Buys $392,301.27 in Stock
www.americanbankingnews.com - May 21 at 7:34 PM
AVEO Pharmaceuticals Inc. (AVEO) Receives Average Recommendation of "Buy" from BrokeragesAVEO Pharmaceuticals Inc. (AVEO) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 19 at 1:34 AM
Audentes Therapeutics and Three More Stocks Under Scanner in the Biotech SpaceAudentes Therapeutics and Three More Stocks Under Scanner in the Biotech Space
finance.yahoo.com - May 18 at 8:39 AM
AVEO Pharmaceuticals (AVEO) Downgraded by BidaskClubAVEO Pharmaceuticals (AVEO) Downgraded by BidaskClub
www.americanbankingnews.com - May 15 at 1:21 PM
Seaport Global Securities Analysts Boost Earnings Estimates for AVEO Pharmaceuticals Inc. (AVEO)Seaport Global Securities Analysts Boost Earnings Estimates for AVEO Pharmaceuticals Inc. (AVEO)
www.americanbankingnews.com - May 14 at 2:48 AM
AVEO Pharmaceuticals Inc. (AVEO) Sees Large Growth in Short InterestAVEO Pharmaceuticals Inc. (AVEO) Sees Large Growth in Short Interest
www.americanbankingnews.com - May 12 at 1:06 AM
FY2018 EPS Estimates for AVEO Pharmaceuticals Inc. (AVEO) Decreased by AnalystFY2018 EPS Estimates for AVEO Pharmaceuticals Inc. (AVEO) Decreased by Analyst
www.americanbankingnews.com - May 11 at 11:05 AM
Insider Buying: AVEO Pharmaceuticals Inc. (AVEO) Major Shareholder Acquires 70,873 Shares of StockInsider Buying: AVEO Pharmaceuticals Inc. (AVEO) Major Shareholder Acquires 70,873 Shares of Stock
www.americanbankingnews.com - May 10 at 8:26 PM
AVEO Pharmaceuticals (AVEO) Releases Quarterly  Earnings Results, Misses Expectations By $0.01 EPSAVEO Pharmaceuticals (AVEO) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - May 10 at 6:12 PM
Q3 2018 EPS Estimates for AVEO Pharmaceuticals Inc. (AVEO) Raised by AnalystQ3 2018 EPS Estimates for AVEO Pharmaceuticals Inc. (AVEO) Raised by Analyst
www.americanbankingnews.com - May 10 at 7:55 AM
AVEO Pharmaceuticals (AVEO) Q1 Loss Wider Than ExpectedAVEO Pharmaceuticals (AVEO) Q1 Loss Wider Than Expected
finance.yahoo.com - May 9 at 5:34 PM
Heres Why AVEO Oncology Fell as Much as 17% TodayHere's Why AVEO Oncology Fell as Much as 17% Today
www.msn.com - May 8 at 5:39 PM
Here's Why AVEO Pharmaceuticals Fell as Much as 17% TodayHere's Why AVEO Pharmaceuticals Fell as Much as 17% Today
finance.yahoo.com - May 8 at 5:39 PM
Heres Why AVEO Pharmaceuticals Fell as Much as 17% TodayHere's Why AVEO Pharmaceuticals Fell as Much as 17% Today
www.fool.com - May 8 at 2:40 PM
AVEO Pharmaceuticals misses by $0.01, misses on revenueAVEO Pharmaceuticals misses by $0.01, misses on revenue
seekingalpha.com - May 8 at 8:16 AM
AVEO Pharmaceuticals Inc. (AVEO) Expected to Post Quarterly Sales of $980,000.00AVEO Pharmaceuticals Inc. (AVEO) Expected to Post Quarterly Sales of $980,000.00
www.americanbankingnews.com - May 8 at 3:36 AM
AVEO Pharmaceuticals Inc. (AVEO) Expected to Announce Earnings of -$0.07 Per ShareAVEO Pharmaceuticals Inc. (AVEO) Expected to Announce Earnings of -$0.07 Per Share
www.americanbankingnews.com - May 6 at 10:12 AM
AVEO Pharmaceuticals (AVEO) Rating Increased to Hold at Zacks Investment ResearchAVEO Pharmaceuticals (AVEO) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - May 5 at 1:09 AM
AVEO Pharmaceuticals Inc. Forecasted to Earn Q1 2018 Earnings of ($0.08) Per Share (AVEO)AVEO Pharmaceuticals Inc. Forecasted to Earn Q1 2018 Earnings of ($0.08) Per Share (AVEO)
www.americanbankingnews.com - May 4 at 5:48 AM
AVEO Pharmaceuticals (AVEO) Upgraded to Buy by ValuEngineAVEO Pharmaceuticals (AVEO) Upgraded to Buy by ValuEngine
www.americanbankingnews.com - May 4 at 12:20 AM
AVEO Pharmaceuticals Inc. Expected to Post Q2 2018 Earnings of ($0.07) Per Share (AVEO)AVEO Pharmaceuticals Inc. Expected to Post Q2 2018 Earnings of ($0.07) Per Share (AVEO)
www.americanbankingnews.com - May 3 at 9:01 AM
AVEO Pharmaceuticals (AVEO) Q1 Earnings: Whats in Store?AVEO Pharmaceuticals (AVEO) Q1 Earnings: What's in Store?
www.zacks.com - April 30 at 8:24 AM
AVEO Pharmaceuticals Inc. (AVEO) Short Interest UpdateAVEO Pharmaceuticals Inc. (AVEO) Short Interest Update
www.americanbankingnews.com - April 27 at 1:24 AM
AVEO Pharmaceuticals Inc. (AVEO) Given Average Rating of "Hold" by AnalystsAVEO Pharmaceuticals Inc. (AVEO) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - April 24 at 1:30 AM
Ex-Aveo Pharmaceuticals CFO must face SEC trial, judge rulesEx-Aveo Pharmaceuticals CFO must face SEC trial, judge rules
www.reuters.com - April 21 at 8:19 AM
SEC seeks to block ex-Aveo CFOs testimony about consulting counselSEC seeks to block ex-Aveo CFO's testimony about consulting counsel
www.reuters.com - April 19 at 8:16 AM
AVEO Pharmaceuticals (AVEO) Upgraded to "Buy" at Zacks Investment ResearchAVEO Pharmaceuticals (AVEO) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 16 at 9:17 PM
AVEO Down 7.7% Since Earnings Report: Can It Rebound?AVEO Down 7.7% Since Earnings Report: Can It Rebound?
finance.yahoo.com - April 12 at 5:39 PM
AVEO Pharmaceuticals (AVEO) Presents At H. C. Wainwright Global Life Sciences Conference - SlideshowAVEO Pharmaceuticals (AVEO) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 11 at 5:32 PM
AVEO Pharmaceuticals (AVEO) Buy Rating Reiterated at Piper JaffrayAVEO Pharmaceuticals' (AVEO) Buy Rating Reiterated at Piper Jaffray
www.americanbankingnews.com - April 10 at 10:31 PM
Insider Buying: AVEO Pharmaceuticals, Inc. (AVEO) Major Shareholder Acquires 685,676 Shares of StockInsider Buying: AVEO Pharmaceuticals, Inc. (AVEO) Major Shareholder Acquires 685,676 Shares of Stock
www.americanbankingnews.com - April 10 at 7:30 PM
Peter J. Barris Purchases 920,976 Shares of AVEO Pharmaceuticals, Inc. (AVEO) StockPeter J. Barris Purchases 920,976 Shares of AVEO Pharmaceuticals, Inc. (AVEO) Stock
www.americanbankingnews.com - April 10 at 7:12 PM
Why AVEO Oncology Jumped Higher TodayWhy AVEO Oncology Jumped Higher Today
finance.yahoo.com - April 9 at 5:22 PM
Moving Average Crossover Alert: AVEO Pharmaceuticals, Inc. (AVEO)Moving Average Crossover Alert: AVEO Pharmaceuticals, Inc. (AVEO)
finance.yahoo.com - April 5 at 10:10 AM
Zacks: Brokerages Anticipate AVEO Pharmaceuticals, Inc. (AVEO) to Post -$0.07 EPSZacks: Brokerages Anticipate AVEO Pharmaceuticals, Inc. (AVEO) to Post -$0.07 EPS
www.americanbankingnews.com - April 2 at 9:12 AM
AVEO Pharmaceuticals, Inc. (AVEO) Receives Average Rating of "Hold" from AnalystsAVEO Pharmaceuticals, Inc. (AVEO) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - March 30 at 1:34 AM
AVEO Pharmaceuticals (AVEO) Lifted to Hold at Zacks Investment ResearchAVEO Pharmaceuticals (AVEO) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - March 29 at 11:18 PM
AVEO Pharmaceuticals (AVEO) Presents At Needham And Company 17th Annual Healthcare Conference - SlideshowAVEO Pharmaceuticals (AVEO) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 5:30 PM
AVEO Pharmaceuticals (AVEO) Rating Reiterated by B. RileyAVEO Pharmaceuticals (AVEO) Rating Reiterated by B. Riley
www.americanbankingnews.com - March 28 at 12:58 PM
AVEO Pharmaceuticals (AVEO) Upgraded to "Sell" by BidaskClubAVEO Pharmaceuticals (AVEO) Upgraded to "Sell" by BidaskClub
www.americanbankingnews.com - March 26 at 5:58 PM
AVEO Pharmaceuticals (AVEO) Stock Rating Lowered by BidaskClubAVEO Pharmaceuticals (AVEO) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - March 25 at 12:52 AM
AVEO Pharmaceuticals (AVEO) Rating Increased to Sell at BidaskClubAVEO Pharmaceuticals (AVEO) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - March 24 at 10:58 AM
Options Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) StockOptions Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) Stock
finance.yahoo.com - March 23 at 5:42 PM
AVEO Oncology Announces Publication of Long-term Follow-up Results from TIVO-1 Extension Study (Study 902) in TKI Refractory RCCAVEO Oncology Announces Publication of Long-term Follow-up Results from TIVO-1 Extension Study (Study 902) in TKI Refractory RCC
finance.yahoo.com - March 21 at 5:38 PM
AVEO Pharmaceuticals (AVEO) Q4 Loss Widens, Shares Down - Yahoo FinanceAVEO Pharmaceuticals (AVEO) Q4 Loss Widens, Shares Down - Yahoo Finance
finance.yahoo.com - March 16 at 8:19 AM
-$0.06 EPS Expected for AVEO Pharmaceuticals, Inc. (AVEO) This Quarter-$0.06 EPS Expected for AVEO Pharmaceuticals, Inc. (AVEO) This Quarter
www.americanbankingnews.com - March 16 at 7:33 AM
Q3 2018 EPS Estimates for AVEO Pharmaceuticals, Inc. Cut by B. Riley (AVEO)Q3 2018 EPS Estimates for AVEO Pharmaceuticals, Inc. Cut by B. Riley (AVEO)
www.americanbankingnews.com - March 15 at 8:15 AM
AVEO Pharmaceuticals, Inc. Forecasted to Earn Q1 2019 Earnings of ($0.05) Per Share (AVEO)AVEO Pharmaceuticals, Inc. Forecasted to Earn Q1 2019 Earnings of ($0.05) Per Share (AVEO)
www.americanbankingnews.com - March 14 at 12:56 PM
BRIEF-Aveo Quarterly Loss Per Share $0.08BRIEF-Aveo Quarterly Loss Per Share $0.08
www.reuters.com - March 13 at 7:17 PM

SEC Filings

AVEO Pharmaceuticals (NASDAQ:AVEO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AVEO Pharmaceuticals (NASDAQ:AVEO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AVEO Pharmaceuticals (NASDAQ AVEO) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.